| Document |
Document Title |
|
WO/2013/158302A1 |
The invention provides derivatives of DEA which have increased potency and hydrolysis resistance as compared to DEA, and compositions thereof, as well as methods of using these derivatives to promote neurogenesis, neurite growth and/or l...
|
|
WO/2013/152476A1 |
Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
|
|
WO/2013/152848A1 |
The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of Pseudomonas aeruginosa infections including respiratory tract infections, urinary tract infections, nosocomia...
|
|
WO/2013/147096A1 |
The present invention provides: a compound represented by formula (I) or a salt thereof; a method for quantitatively analyzing a target substance containing an amino group, which comprises labeling the target substance in at least two sa...
|
|
WO/2013/144394A1 |
Alternariol and alternariol monomethyl ether are two of the toxins produced in greatest amounts by fungi of the family Alternaria. They occur frequently in foodstuffs and continued consumption thereof may have negative effects on human h...
|
|
WO/2013/146539A1 |
According to the present invention, PPARs agonist activity is enhanced in order to improve metabolic syndrome, hyperlipidemia, and diabetes. Provided is a compound having a lactone structure comprising formula (9).
|
|
WO/2013/142812A1 |
The invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and G are as described in the specification, as well as compositions comprising a compound of formula I, methods of...
|
|
WO/2013/134415A1 |
The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and m...
|
|
WO/2013/130792A2 |
Fluorinated prodrug compounds as can be used for selective streptococcal mevalonate pathway inhibition.
|
|
WO/2013/125356A1 |
Provided are: a liquid crystal compound which has high stability with respect to heat, light and the like, high clearing point, low lower limit temperature of the liquid crystal phase, low viscosity, adequate optical anisotropy, large di...
|
|
WO/2013/125777A1 |
The present invention relates to a biosynthetic gene cluster for a chejuenolide of the marine microorganism Hahella chejuensis, and to the function of an enzyme involving the biosynthetic pathway of a chejuenolide coded by the genes. Sin...
|
|
WO/2013/122028A1 |
The purpose of the present invention is to provide an aromatic ring compound exhibiting GPR40 agonist activity. The compound represented by formula (I) (refer to the description for information pertaining to each symbol in the formula) o...
|
|
WO/2013/118907A1 |
An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups that ar...
|
|
WO/2013/118905A1 |
An amide compound represented by formula (I) has an excellent pest control effect. (In the formula, Y represents a 3-7 membered saturated heterocyclic ring which contains, as ring-forming component(s), one or more atoms or groups that ar...
|
|
WO/2013/073483A9 |
[Problem] To impart significantly improved myo-inositol producing capability, suitable for use in recombinant DNA techniques and synthetic biology methods, to a host microorganism that does not possess an endogenous myo-inositol biosynth...
|
|
WO/2013/106029A1 |
The present application discloses new taxane analogs, intermediates and methods for producing them. The present application is also directed to pharmaceutical formulations comprising abeo-taxanes and methods of treating cancer with the a...
|
|
WO/2013/063679A9 |
Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid ...
|
|
WO/2013/103668A1 |
In accordance with the present invention, there are provided compositions comprising zanamivir and at least one permeability enhancer. The compositions can increase the amount of zanamivir capable of being transported across a cell membr...
|
|
WO/2013/097424A1 |
Provided are a marine streptomyces sp., a compound of pyranosesquiterpenes and a preparation method and the use thereof. Streptomyces sp. SCSIO 01689 was deposited in the China Center for Type Culture Collection (CCTCC) on July 18, 2011,...
|
|
WO/2013/096971A1 |
The discovery of distinct modes of asymmetric catalysis has the potential to rapidly advance chemists' ability to build enantioenriched molecules. As an example, the use of chiral cation salts as phase-transfer catalysts for anionic reag...
|
|
WO/2013/092941A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds f...
|
|
WO/2013/093320A1 |
The invention relates to the use of 1-aryl-2-aryloxyethane compounds with formula I, wherein n and m are equal to 0 or 1, provided that n+m=1, R1 and R2 particularly representing hydrogen atoms, R3 and R4 particularly representing hydrog...
|
|
WO/2013/089168A1 |
The present invention provides a method for producing a neuraminic acid derivative. A method for producing a compound represented by formula (I) [wherein R1 represents a C1-C19 alkyl group] or a pharmacologically acceptable salt thereof ...
|
|
WO/2013/088972A1 |
Provided is a compound represented by general formula (1). (1) In general formula (1), R1 is either a protecting group for a hydroxyl group or a hydrogen atom. R2 is either a methyl group or an ethyl group.
|
|
WO/2013/079501A1 |
The present invention is directed to crystalline dapagliflozin hydrate and a process for obtaining the same. Dapagliflozin has the structure of formula (I).
|
|
WO/2013/079708A1 |
The present invention relates to a compound of formula (I): wherein: X is methyl or chlorine; R1 is methyl or chlorine; R2 is hydrogen, methyl, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, fluorine, chlorine, bromine, methoxy, ethoxy or...
|
|
WO/2013/075400A1 |
Disclosed is a liquid crystal compound. The compound has a general structural formula as shown by formula I. Such a compound has good thermal and UV stability, large positive dielectric anisotropy △ε, and can achieve a low threshold v...
|
|
WO/2013/070911A1 |
The invention features novel compounds useful for the treatment or prevention of cystic fibrosis. Further, the invention also relates to methods, kits and packaged compositions for the treatment or prevention of cystic fibrosis in a subj...
|
|
WO/2013/068917A1 |
The present application relates to a process for the preparation of lactones by enzymatic oxidation of lactols. The lactones, produced thus may be useful for the synthesis of statins, including but not limited to, cerivastatin, pitavasta...
|
|
WO/2013/064538A1 |
The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally subs...
|
|
WO/2013/063127A1 |
The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or ...
|
|
WO/2013/060805A1 |
The invention relates to a method for producing a composition enriched in cis-2-(2-methyl-prop-1-en-yl)-4-methyl-tetrahydropyran, comprising the catalytic hydrogenation of 2-(2-methyl-prop-1-en-yl)-4-methylene tetrahydropyran in the pres...
|
|
WO/2013/060653A1 |
This invention relates to novel 1-cycloalkyl- or l-heterocyclyl-hydroxyimino-3-phen propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These...
|
|
WO/2013/061919A1 |
The purpose of the present invention is to provide: a novel compound useful as an anti-mold substance; and a method for producing the compound. The present invention relates to: a compound represented by formula (I0) (wherein R1 represen...
|
|
WO/2013/057320A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a n...
|
|
WO/2013/054366A1 |
The present invention relates to a simple, economical and short synthesis for the class of compounds chemically belonging to amino acrylic acids of general formula I exhibiting both antibacterial and anti-plasmodium (anti-malarial) activ...
|
|
WO/2013/055577A1 |
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
|
|
WO/2013/052700A1 |
This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase.
|
|
WO/2013/028570A2 |
The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anand...
|
|
WO/2013/022919A1 |
A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.
|
|
WO/2013/021018A1 |
The present invention concerns compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly...
|
|
WO/2013/022047A1 |
The present invention provides a compound which has an inhibitory activity on lysine-specific demethylase 1 and is useful as a medicinal agent such as a prophylactic or therapeutic agent for cancer and central nervous system diseases. Th...
|
|
WO/2013/016120A1 |
Compounds that include a pederin, psymberin or pederin/psymberin chimera scaffold. The pederin scaffold includes a substituent at the C10 and/or C13 position that may include a linker that may be conjugated to a targeting moiety. The psy...
|
|
WO/2013/014565A1 |
The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. These salts may be formulated as pharmaceutical compositions....
|
|
WO/2013/015388A1 |
The purpose of the present invention is to provide a novel NDM (New Delhi metallo-β-lactamase) inhibitor as a drug for restoring the antibacterial activity of a β-lactam antibiotic that has been inactivated due to degradation by NDM. T...
|
|
WO/2013/014354A1 |
The invention relates to ceramide-analogue compounds which have a cyclic structure derived from cyclopropane, from cyclobutane or from cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is link...
|
|
WO/2013/007792A1 |
The present invention relates to a pharmaceutical composition, particularly to a pharmaceutical composition for use in the treatment and/or prevention of immune-mediated diseases which are characterized by a Th1 environment such as autoi...
|
|
WO/2013/005817A1 |
Disclosed is a method for manufacturing a fatty acid derivative represented by formula (I): which comprises the step of, reacting a compound of formula (II): with a co-oxidizer under the presence of an azaadamantane-N-oxyl derivative. Ac...
|
|
WO/2012/161178A1 |
The invention relates to a compound having a 2-fluorophenyloxymethane structure that is useful as an organic electronic material, pharmaceutical, or agrochemical, particularly a material for a liquid crystal display element. The problem ...
|
|
WO/2012/155199A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
